The FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new indication, setting up a possible approval by 4 June. The new indication for Recarbrio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback